Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies
Status: Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 01 Mar 2019
Price : $35 *
At a glance
- Drugs Dendritic cell vaccines (Primary) ; Interleukin-2 (Primary) ; Pembrolizumab (Primary)
- Indications Mesothelioma
- Focus Adverse reactions; Pharmacodynamics
- Acronyms MESOVAX
- 26 Feb 2019 Planned initiation date changed from 1 Jan 2019 to 1 Apr 2019.
- 08 Nov 2018 Planned initiation date changed from 1 Aug 2018 to 1 Jan 2019.
- 11 Jun 2018 New trial record